DCB for Coronary ISR Impact of Lesion Preparation Bruno Scheller
|
|
- Rosemary Robinson
- 6 years ago
- Views:
Transcription
1 DCB for Coronary ISR Impact of Lesion Preparation Bruno Scheller Klinische und Experimentelle Interventionelle Kardiologie, Universität des Saarlandes, Campus Homburg Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes Homburg / Saar, Germany
2 Speaker s name: Bruno Scheller X I have the following potential conflicts of interest to report: X Research contracts (B.Braun, MDT Invatec, AngioScore) Consulting Employment in industry X Stockholder of a healthcare company (InnoRa GmbH) Owner of a healthcare company X Other(s): coinventor in several patent applications I do not have any potential conflict of interest
3 European Heart Journal doi: /eurheartj/ehu278
4 JACC Cardiovasc Interv 2012; 5:
5 Lancet. 2013; 381: 461-7
6 Am Coll Cardiol Intv 2015; epub
7 Lancet, 2015; 386:
8 Alfonso, J Am Coll Cardiol 2015; 66: 23-33
9 RIBS IV Experience of operators with DCB Learning Curve Drug loss in blood (time from insertion in guiding cath till deployment), only 3.2% cross-over Lesion preparation 50% diameter stenosis accepted in DCB group >10% of pts with restenosis just at baseline inflation pressure significantly lower in the DCB group high pressure postdilatation in EES group by protocol Acute gain RIBS V RIBS IV Paccocath ISR PEPCAD DES PEPCAD II PEPCAD China Vessel Refer. Diameter Acute Gain Bruno Scheller, Paul Ong, Franz X Kleber: Letter to the editor. J Am Coll Cardiol 2015; in press
10 Catheter Cardiovasc Interv. 2014; 83: 881-7
11 Specialty Balloons AngioSculpt Chocolate
12 Catheter Cardiovasc Interv Nov 21. doi: /ccd [Epub ahead of print]
13 Catheter Cardiovasc Interv Sep 2. doi: /ccd [Epub ahead of print]
14 ISAR DESIRE IV Byrne, TCT 2015
15 ISAR DESIRE IV Byrne, TCT 2015
16 SQP SVD Japan Atsushi FUNATSU. CCT, Kobe, Japan, 2015
17 SQP SVD Japan Atsushi FUNATSU. CCT, Kobe, Japan, 2015
18 SQP SVD Japan Atsushi FUNATSU. CCT, Kobe, Japan, 2015
19 Lancet. 2013; 381: 461-7
20 EES DCB Binary restenosis 11 % 19 % TLR 4 % 13 % TLR/restenosis 47 % 74 % There is a possibility, however, that the indication for reinterventions at follow-up would have been influenced by their perceived risk benefit. Treating recurrent ISR in patients with a double metal layer [ ] might be considered as less attractive than treating ISR after BA failure. Alfonso F. J Am Coll Cardiol 2015; 66: Alfonso F, Cuesta J. JACC Cardiovascular interventions 2015; 8:
21 JACC CI 2014; 7: Zhao TCT 2014
22 JACC: Cardiovasc Int 2015; epub ahead of print
23 JACC: Cardiovasc Int 2015; epub ahead of print
24 JACC Cardiovasc Int 2013; 6:
25 Stent thrombosis after treatment of ISR Study (pts per group) Richardt et al. (n=281) Type of ISR treatment Follow-up stent thrombosis Reference BMS- and DES-ISR ZES 1 year 2 years 2.1% 2.5% JACC Cardiovasc Int 2013;6: PACCOCATH ISR (n=54) BMS-ISR DCB (paclitaxel iopromide) 6 years 0 JACC Cardiovasc Int 2012;5: PEPCAD II (n=66) BMS-ISR DCB (paclitaxel iopromide) Habara et al. (n=25) DES-ISR DCB (paclitaxel iopromide) 3 years 0 In press 6 months 0 JACC Cardiovasc Int 2011;4: PEPCAD DES (n=72) DES-ISR DCB (paclitaxel iopromide) 6 months 1.4% (1 case, possible) J Am Coll Cardiol 2012;59: ISAR DESIRE III (n=131) DES-ISR DCB (paclitaxel iopromide) 1 year 0.7% (1 case) Lancet 2013;381:461-7 PEPCAD Japan (n=136) BMS- and DES-ISR DCB (paclitaxel iopromide) 6 months 0 Am Heart J 2013; 166: SQP Word Wide Registry (n=1,523) BMS- and DES-ISR DCB (paclitaxel iopromide) 9 months 0.1% (2 cases) J Am Coll Cardiol 2012;60: DCB overall (n=2,007) DCB (paclitaxel iopromide) 0.2 % (4 cases) JACC Cardiovasc Int 2013; 6: Comment on TCTMD.com August 14 th 2013.
26 DCB for coronary ISR lessons to learn Operator experience (drug loss in blood) Lesion preparation Impact of endpoint definition Ironically, this major advantage of DCB, namely the repeatability of the procedure, leads to a significant disadvantage in endpoints that include surrogates like TLR and not hard endpoints only. However, randomized comparisons report a long-term survival benefit for DCB in DES-ISR treatment. Bruno Scheller, Paul Ong, Franz X Kleber: Letter to the editor. J Am Coll Cardiol 2015; in press
27 DCB treatment default strategy for ISR avoids several layers of metal reduces the need for prolonged dual antiplatelet therapy repeatability of the procedure positively influences hard endpoints on long-term disadvantage in angiographic outcomes should be limited by careful lesion preparation assuring sufficient initial lumen gain. Bruno Scheller, Paul Ong, Franz X Kleber: Letter to the editor. J Am Coll Cardiol 2015; in press
Challenges of in-stent Restenosis. The Balloon Approach
Challenges of in-stent Restenosis The Balloon Approach Bruno Scheller Klinische und Experimentelle Interventionelle Kardiologie, Universität des Saarlandes, Campus Homburg Klinik für Innere Medizin III,
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationProvisional T- sten/ng Future Outlook: Ra/onale of Plaque Incision + DCB
Provisional T- sten/ng Future Outlook: Ra/onale of Plaque Incision + DCB Dr. Azeem La/b EMO- GVM Centro Cuore Columbus and San Raffaele Scien/fic Ins/tute, Milan, Italy PCI in Coronary Bifurca/ons Up to
More informationINTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS
INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS Table of Contents Overview SeQuent Please - DCB Scientific Publications SeQuent Please
More informationPCI with DEB only for Bifurcation Lesions
PCI with DEB only for Bifurcation Lesions Franz X. Kleber MD, FESC, Berlin, DE Disclosure: Consulting B.Braun Why did we adapt an all stent approach in bifurcations? - because it is safe - because it leads
More informationIn 1977, coronary angioplasty revolutionized the
Current Use of Coronary Drug-Coated Balloons A review of technical considerations and clinical applications and a discussion of what s next in drug-coated balloon technology. BY ROBERT M. BERSIN, MD, MPH
More informationSeQuent Please World Wide Registry
Journal of the American College of Cardiology Vol. 6, No. 18, 212 212 by the American College of Cardiology Foundation ISSN 735-197/$36. Published by Elsevier Inc. http://dx.doi.org/1.116/j.jacc.212.7.4
More informationNext Generation of DCB: Efficacy and tolerance of drug-coated hyper-compliant balloons (DCHCB) in peripheral arteries of swine
Next Generation of DCB: Efficacy and tolerance of drug-coated hyper-compliant balloons (DCHCB) in peripheral arteries of swine Maciej Kusmierczuk 1 ; Stephanie Bienek, PhD 1 ; Sebastian Schurmann 1 ; Antje
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationComplex PCI. Your partner in complex PCI: In-stent restenosis (ISR)
Comple PCI Your partner in comple PCI: Your partner in comple PCI: Philips provides a portfolio of specialty coronary diagnostic and therapy devices that enable safe and effective treatment of a wide variety
More informationDRUG-COATED BALLOONS AND CORONARY BIFURCATION LESIONS
DRUG-COATED BALLOONS AND CORONARY BIFURCATION LESIONS *Alessandro Durante, 1 Pietro Leonida Laforgia 2 1. Ospedale Valduce, Como, Italy 2. Università degli Studi di Milano, Milan, Italy *Correspondence
More informationDavide Capodanno, MD, PhD Associate Professor, University of Catania, Italy
Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 1 Autumn in Lucca V Simposio - 28 Novembre 2014 4.30PM-4.45PM L incubo del paziente e le incognite del cardiologo: la restenosi intrastent resta
More informationNon stent based intracoronary drug delivery
Non stent based intracoronary drug delivery Dariusz Dudek Department of Interventional Cardiology Jagiellonian University, Krakow, Poland The European Association of Percutaneous Cardiovascular Interventions
More informationIn-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»
In-stent Restenosis Diagnostic and Therapeutic Challenges Kostis Raisakis General Hospital of Athens «G. Gennimatas» Introduction With POBA, rates of acute and chronic vessel occlusion at 30% to 60%, secondary
More informationPaclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 2285-2292, 2015 Paclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data JUN LI, WAN
More informationOne Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller
One Year after In.Pact Deep: Lessons learned from a failed trial Prof. Dr. Thomas Zeller Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: x Consulting:
More informationDrug-Coated Balloons: Clinical Role in Coronary and Peripheral Interventional Therapy
Drug-Coated Balloons: Clinical Role in Coronary and Peripheral Interventional Therapy Juan F. Granada, MD Executive Director and Chief Scientific Officer Skirball Center for Cardiovascular Research Cardiovascular
More informationRevolutioniert der medikamentenfreisetzende Ballon (DEB) die interventionelle Therapie der KHK?
Revolutioniert der medikamentenfreisetzende Ballon (DEB) die interventionelle Therapie der KHK? Dr. med. Bodo Cremers Klinik für Innere Medizin III Kardiologie, Angiologie und Internistische Intensivmedizin
More informationUpdate from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationClinical benefits on DES Patient s perspectives
Clinical benefits on DES Patient s perspectives Dr. Skyi Pang Vascular Surgeon Department of Surgery Pamela Youde Nethersole Eastern Hospital Hong Kong Disclosure Speaker name: Skyi Pang... I have the
More informationProspective, randomized controlled study of paclitaxel-coated versus plain balloon angioplasty for the treatment of failing dialysis access
Prospective, randomized controlled study of paclitaxel-coated versus plain balloon angioplasty for the treatment of failing dialysis access Disclosure Speaker name:... I have the following potential conflicts
More informationFuture Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit? John R. Laird Adventist Heart and Vascular Institute St. Helena, CA Disclosure Speaker name: John R. Laird... I have
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationXPEDITE Clinical Study PaclitaXel-coated Peripheral StEnts used In the Treatment of FemoropoplitEal Stenoses
XPEDITE Clinical Study PaclitaXel-coated Peripheral StEnts used In the Treatment of FemoropoplitEal Stenoses Thomas Zeller, M.D. Universitäts-Herzzentrum Freiburg-Bad Krozingen, Germany Disclosure Speaker
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationMassimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany
Intravascular Stenting and Angiographic Results: Randomized Comparison of STenting, Stenting after Paclitaxel-eluting balloon and ATHerectomy in patients with symptomatic Peripheral Artery Disease - Results
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationa drug-coated scoring balloon for coronary use
Cardiologia Interventistica A.O. Fatebenefratelli one medicato rappresenta una one nella cardiologia interventistica, tte di trattare lesioni in cui lo stent antisce un risultato ottimale. o che tuttora
More informationThe importance of scientific evidence. Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern
The importance of scientific evidence Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner... I have the following potential
More informationImportance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study
Importance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study Gunnar Tepe, MD Romed Klinikum, Rosenheim, Germany On behalf of the DEFINITIVE AR
More informationTratamiento de la Reestenosis del Stent Farmacoactivo
XXXI Jornadas SOLACI. 10ª Región CONOSUR LIIIº Congreso Chileno de Cardiología y Cirugía Cardiovascular Hotel Patagónico. Puerto Varas. Chile (30 Nov 1 Dic 2016) Tratamiento de la Reestenosis del Stent
More informationDrug eluting balloon for bifurcation lesion: is it useful?
Welcome to the 8 th European Bifurcation Club 12-13 October 2012 - Barcelona Drug eluting balloon for bifurcation lesion: is it useful? Dr. Bruno Garcia Hospital Universitari Vall Hebrón Barcelona (Spain)
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationLessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationΑγγειοπλαστική με απλό μπαλόνι και με μπαλόνια που αποδεσμέουν φαρμακευτική ουσία.
7 ο Συνέδριο Επεμβατικής Καρδιολογίας και Ηλεκτροφυσιολογίας, Καρδιολογική Εταιρεία Βορείου Ελλάδος, 9-11/10/2014, Θεσσαλονίκη Αγγειοπλαστική με απλό μπαλόνι και με μπαλόνια που αποδεσμέουν φαρμακευτική
More informationZilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results
Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results Hiroyoshi Yokoi, MD, Fukuoka Sannou Hospital Fukuoka, Japan On behalf
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationINSIDE INFORMATION YOU CAN T IGNORE
INSIDE INFORMATION YOU CAN T IGNORE Volcano, the Volcano logo and SyncVision are registered trademarks of Volcano Corporation. All other trademarks set-forth are properties of their respective owners.
More informationPlaque scoring in calcified lesions
Plaque scoring in calcified lesions Advancing DCB therapy in complex SFA lesions Erwin Blessing, MD, FESC SRH Klinikum Karlsbad- Langensteinbach, Germany Disclosure Speaker name: Erwin Blessing I have
More informationMaximizing Outcomes in a complex population with Drug-coated balloon
Maximizing Outcomes in a complex population with Drug-coated balloon March 13, 2018 Chumpol Wongwanit, MD Siriraj Hospital, Mahidol University, Bangkok, Thailand LINC Asia-Pacific 2018, Hong Kong Disclosure
More informationThe role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium
The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium Disclosures Speaker name: Frank Vermassen I have the following potential
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationBTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration
BTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration M Sapoval, C Del Giudice, C Dean Interventional Radiology Dep Hôpital Européen Georges Pompidou APHP, Paris, France IMPORTANT
More informationISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany
ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich I have the following
More informationComparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions
Comparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions Michinao Tan, MD Tokeidai Memorial Hospital Cardiovascular
More informationKlinikum Rosenheim Department of Diagnostic and Interventional Radiology
Klinikum Rosenheim Department of Diagnostic and Interventional Radiology Is Directional Atherectomy (Silverhawk Or Turbohawk) With DEB, Better Than DEB Alone: Based On The DEFINITIVE AR RCT: 1-Year Results
More informationVessel preparation with scoring balloons prior to DCB or stenting
Vessel preparation with scoring balloons prior to DCB or stenting Deep dive session: lower limb interventions Erwin Blessing, MD, FESC SRH Klinikum Karlsbad- Langensteinbach, Germany Disclosure Speaker
More informationDrug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND Drug eluting stents and balloons Endovascular treatment now becoming more popular for treatment
More informationILLUMENATE FIH Direct DCB Cohort 12-Month Results
ILLUMENATE FIH Direct DCB Cohort 12-Month Results Stephan Duda Berlin Study Investigators: H. Schröder (PI), B. Lux, F. Rücker, M. Martorana, D. Meyer, H. Hartmann, S. Duda Disclosure Speaker name: S.
More informationContemporary therapy of bifurcation lesions
Contemporary therapy of bifurcation lesions Dr Angela Hoye MB ChB PhD MRCP Interventional Cardiologist Kingston-upon-Hull, UK Hull The challenge of bifurcations Risk of peri-procedural infarction Relatively
More informationClinical Considerations for CTO
38 RCTs Clinical Considerations for CTO 18,000 pts Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD FACC, FSCAI Director, Interventional Cardiology Research
More informationCutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD
Current Treatment of Femoropopliteal Instent Restenosis Professor of Medicine Medical Director of the Vascular Center UC Davis Medical Center SFA In-stent Restenosis Common: 18%- 40% at 12 months in recent
More informationLong-term Zilver PTX Data from Japan: 5-year Results in the Real World
Long-term Data from Japan: 5-year Results in the Real World Hiroyoshi Yokoi, MD Department of Cardiovascular Medicine Fukuoka Sanno Hospital Fukuoka, Japan On behalf of the Investigators Disclosure Speaker
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationDrug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2
Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2 Raban V. Jeger,Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, GregorLeibundgut, Daniel Weilenmann, JochenWöhrle,
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationThe latest evidences from the DES trials in peripheral arterial disease
The latest evidences from the DES trials in peripheral arterial disease Michael D. Dake, MD Thelma and Henry Doelger Professor Stanford University School of Medicine Disclosure Speaker name: Michael D.
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationCTO Re vascularization in 2013
CTO Re vascularization in 2013 Is it safe to use/stent the sub intimal space? Dimitri Karmpaliotis, MD, FACC, FSCAI Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia Dimitri.karmpaliotis@piedmont.org
More informationTHE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES
THE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES THE IDEA AND THE TECHNOLOGY FRANCESCO JATTA, PH.D. PROGRAM MANAGER DISCLOSURES I have the following potential conflicts of interest to report: Consulting
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationNeuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology
Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic
More informationAccurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery
Accurate Vessel Sizing Drives Clinical Results IVUS In the Periphery Discussion Iida O, et. al. Study Efficacy of Intravascular Ultrasound in Femoropopliteal Stenting for Peripheral Artery Disease With
More informationLutonix AV Clinical Trial
Long Term Effects of LUTONIX 035 DCB Catheter Interim 24 Month Results Scott O. Trerotola, MD, for the Lutonix AV Investigators Stanley Baum Professor of Radiology Professor of Radiology in Surgery Associate
More informationBioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
More informationShockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis
Shockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More informationLuminor DCB in femoropopliteal lesions
Luminor DCB in femoropopliteal lesions EffPac trial results and solo DCB study design Marcus Thieme, MD Department of Angiology/ Cardiology/ Diabetology Regiomed Vascular Center Sonneberg Clinic for Internal
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationDo we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More informationHow do I use mechanical debulking for the treatment of arterial occlusions
How do I use mechanical debulking for the treatment of arterial occlusions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
More informationDrug delivery devices for BTK treatment
LINC AP 2016, Hong Kong A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Drug delivery devices for BTK treatment Patrick Peeters Jürgen Verbist W. Van
More informationVessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA Disclosure Statement of Financial Interest Within the past 12 months,
More informationLutonix AV Clinical Trial
Long Term Effects of LUTONIX 035 DCB Catheter Interim 24 Month Results Ta-Wei Su MD Vascular surgery CGMH Taiwan Disclosure I have the following potential conflicts of interest to report: Consulting Employment
More informationProtection of side branch is essential in treating bifurcation lesions: overview
Angioplasty Summit TCT Asia Pacific Seoul, April 26-28, 2006 Protection of side branch is essential in treating bifurcation lesions: overview Alfredo R Galassi, MD, FACC, FSCAI, FESC Head of the Catetherization
More informationUpdate on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria
Update on the OPTIMIZE BTK Trial Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann, MD... I have the following potential conflicts
More informationEffectiveness of Paclitaxel-Eluting Balloon Catheter in Patients With Sirolimus-Eluting Stent Restenosis
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 2, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.10.012 CLINICAL RESEARCH
More informationLong inflation to left main coronary artery with kissing balloon inflation by drug-coated balloon and perfusion balloon
com Nakabayashi et al. 1 Original case report Article Peer Reviewed OPEN ACCESS Long inflation to left main coronary artery with kissing balloon inflation by drug-coated balloon and perfusion balloon Keisuke
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationAngiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-
Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis- Masahiko Fujihara Kishiwada Tokushukai Hospital, Osaka, Japan Disclosure
More informationUpdate on the role of drug eluting balloons
Update on the role of drug eluting balloons William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular Research
More informationGoal: Optimal Stent Deployment
Ground breaking, Life changing Goal: Optimal Stent Deployment Ground breaking, Life changing Cordis Corporation has no independent knowledge concerning the information contained in these presentations.
More informationin an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore
Unrelenting Left Main Disease in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore Clinical History 72 years old Chinese lady Background and CV Risk
More informationRANGER SFA REGISTRY Interim Analysis. Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators
RANGER SFA REGISTRY Interim Analysis Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationIntracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington.
Intracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington. Medstar Washington Hospital Center Washington, DC Conflict of Interest None for this
More informationMichael K.W. Lichtenberg, MD
Ranger All-Comer Registry Treatment of femoropopliteal atherosclerotic lesions using the Drug eluting Balloon Ranger: An All Comers Registry Michael K.W. Lichtenberg, MD Klinikum Arnsberg Arnsberg, Germany
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationSunao Nakamura M.D,Ph.D.
Drug Eluting Stent Implantation For Unprotected Left ain Coronary Arteries New Tokyo Circulation Research Group New Tokyo Hospital Sunao Nakamura.D,Ph.D. Drug-Eluting Stent for Left ain Coronary Artery
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More information